ATE364699T1 - Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen - Google Patents

Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen

Info

Publication number
ATE364699T1
ATE364699T1 AT96942732T AT96942732T ATE364699T1 AT E364699 T1 ATE364699 T1 AT E364699T1 AT 96942732 T AT96942732 T AT 96942732T AT 96942732 T AT96942732 T AT 96942732T AT E364699 T1 ATE364699 T1 AT E364699T1
Authority
AT
Austria
Prior art keywords
humanized antibodies
compositions containing
antibodies against
against human
therapeutic uses
Prior art date
Application number
AT96942732T
Other languages
English (en)
Inventor
Amelia Black
Nabil Hanna
Eduardo Padlan
Roland Newman
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE364699T1 publication Critical patent/ATE364699T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96942732T 1995-11-07 1996-11-07 Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen ATE364699T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/554,840 US6001358A (en) 1995-11-07 1995-11-07 Humanized antibodies to human gp39, compositions containing thereof

Publications (1)

Publication Number Publication Date
ATE364699T1 true ATE364699T1 (de) 2007-07-15

Family

ID=24214905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942732T ATE364699T1 (de) 1995-11-07 1996-11-07 Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen

Country Status (11)

Country Link
US (4) US6001358A (de)
EP (1) EP0862630B1 (de)
JP (1) JP2000500334A (de)
KR (1) KR100389711B1 (de)
AT (1) ATE364699T1 (de)
AU (1) AU717762B2 (de)
DE (1) DE69637131T2 (de)
HU (1) HUP9902327A3 (de)
NO (1) NO324272B1 (de)
NZ (1) NZ324500A (de)
WO (1) WO1997017446A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20030099642A1 (en) * 1996-04-22 2003-05-29 Michael J. Yellin Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis
EA004401B1 (ru) * 1996-07-08 2004-04-29 Дзе Трастиз Оф Колумбия Юниверсити Ин Дзе Сити Оф Нью Йорк Терапевтическое применение т-вам(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры
CA2277223A1 (en) * 1997-01-10 1998-07-16 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
SK156099A3 (en) * 1997-05-17 2000-06-12 Biogen Inc Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
ATE211394T1 (de) 1997-06-20 2002-01-15 Tanox Pharma B V Anti-cd40l immunotoxine zur behandlung von krankheiten
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
EP0937463A1 (de) * 1998-02-18 1999-08-25 The Procter & Gamble Company Zusammensetzungen für die Hautversorgung
CN100352497C (zh) * 1998-04-03 2007-12-05 达特茅斯学院理事 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
KR20020072277A (ko) * 1999-11-08 2002-09-14 아이덱 파마슈티칼즈 코포레이션 항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1284747A2 (de) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Zusammensetzungen und verfahren zur erzielung einer immunsuppression
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP2004502742A (ja) * 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
CN101275136A (zh) * 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
JP4435563B2 (ja) * 2001-07-10 2010-03-17 バイオジェン アイデック インク アポトーシスプロセスの阻害および細胞性能の改善
ATE420964T1 (de) 2001-11-16 2009-01-15 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
DE60329070D1 (de) * 2001-12-28 2009-10-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen den fibroblastenwachstumsfaktor 23
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
WO2003086463A1 (en) * 2002-04-03 2003-10-23 Keio University Remedies for pemphigus containing cd40l antagonist as the active ingredient
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
CA2579391C (en) 2004-09-06 2010-10-26 Kirin Beer Kabushiki Kaisha Anti-a33 antibody
EP1819732A2 (de) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Humane monoklonale influenza-m2-protein-antikörper und verfahren zu deren herstellung und verwendung
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
BRPI0608468A2 (pt) * 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
EP1888649A2 (de) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen-bindungsmoleküle mit modifizierten fc-regionen und veränderte bindung an fc-rezeptoren
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2006380A4 (de) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd Gegen menschlichen thrombopoetin-rezeptor gerichteter agonistischer antikörper
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
KR20090029227A (ko) 2006-06-06 2009-03-20 교와 핫꼬 기린 가부시키가이샤 헤파린 결합 상피세포 증식 인자 유사 증식 인자에 결합하는 모노클로날 항체
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
EP2484696B1 (de) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
JP5081462B2 (ja) * 2007-02-02 2012-11-28 富士フイルム株式会社 トランススプライシング法による融合タンパク質作製方法
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
ES2475201T3 (es) * 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
EP2367849B1 (de) 2008-12-05 2017-11-01 ALS Therapy Development Institute Methode zur behandlung von neurodegenerativen erkrankungen
MX2011009620A (es) 2009-03-31 2011-10-19 Roche Glycart Ag Tratamiento de cancer con un anticuerpo de inmunoglobulina g1 (igg1) humanizado anti receptor de factor de crecimiento epidermico (anti-egfr) e irinotecan.
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
RU2583876C2 (ru) * 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
CA2770174A1 (en) * 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
EP2554669B1 (de) 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Neuer antikörper mit darin eingeführter modifikationsstelle und antikörperfragment
EP2578232A4 (de) 2010-06-02 2013-11-20 Dainippon Sumitomo Pharma Co Behandlungsmittel für autoimmun-erkrankungen und allergische erkrankungen
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
US9321833B2 (en) * 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
WO2012176779A1 (ja) 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
CN105555802B (zh) 2012-11-19 2020-08-28 淡马锡生命科学研究院有限公司 靶向h7流感病毒上中和表位的单克隆抗体
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
SG10201913431QA (en) 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
EP3231814B1 (de) * 2016-04-14 2020-02-26 BioGenes GmbH Verfahren zur herstellung von antigenspezifischen b-zellen und deren verwendung zur herstellung von hybridomazellen und monoklonaler antikörper
EP3630843A2 (de) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutische anti-cd40-ligand-antikörper
EP3653713A4 (de) 2017-07-13 2021-03-31 Kyowa Kirin Co., Ltd. Anti-bril-antikörper und verfahren zur stabilisierung des bril-fusionsproteins mit diesem antikörper
US11912775B2 (en) 2017-07-18 2024-02-27 Kyowa Kirin Co., Ltd. Anti-human CCR1 monoclonal antibody
AU2018363922B2 (en) 2017-11-08 2025-06-12 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
CA3104997A1 (en) 2018-06-26 2020-01-02 Kyowa Kirin Co., Ltd. Antibody binding to chondroitin sulfate proteoglycan 5
WO2020067541A1 (ja) 2018-09-28 2020-04-02 協和キリン株式会社 抗体組成物
KR102991359B1 (ko) 2018-12-28 2026-07-16 쿄와 기린 가부시키가이샤 TfR에 결합하는 이중 특이적 항체
WO2020230901A1 (ja) 2019-05-15 2020-11-19 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
CA3140385A1 (en) 2019-05-15 2020-11-19 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and fap
CN114502739A (zh) 2019-10-02 2022-05-13 国立大学法人九州大学 肝素样物质的制造方法、重组细胞及其制造方法
TWI888487B (zh) 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
TWI884247B (zh) 2020-04-01 2025-05-21 日商協和麒麟股份有限公司 抗體組合物
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
TW202317637A (zh) 2021-08-26 2023-05-01 日商協和麒麟股份有限公司 與cd116及cd131結合之雙特異性抗體
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
CA3252263A1 (en) 2022-02-09 2025-07-07 National Institutes Of Biomedical Innovation, Health And Nutrition ANTIBODY OR FRAGMENT OF IT BINDING TO FCRL1
CN119677855A (zh) 2022-08-10 2025-03-21 协和麒麟株式会社 抗fgf23抗体或该抗体片段
KR20260116248A (ko) 2023-11-28 2026-07-28 엘레던 파마슈티컬즈, 아이엔씨. 이식 거부반응 예방을 위한 방법 및 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP2840131B2 (ja) 1993-09-02 1998-12-24 トラスティーズ・オブ・ダートマス・カレッジ 液性免疫の持続性抑制方法
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies

Also Published As

Publication number Publication date
NZ324500A (en) 1999-08-30
JP2000500334A (ja) 2000-01-18
HUP9902327A3 (en) 2000-12-28
NO982062L (no) 1998-07-06
US7074406B2 (en) 2006-07-11
DE69637131D1 (de) 2007-07-26
KR19990067370A (ko) 1999-08-16
US6001358A (en) 1999-12-14
NO324272B1 (no) 2007-09-17
US6506383B1 (en) 2003-01-14
WO1997017446A3 (en) 1997-09-25
AU717762B2 (en) 2000-03-30
US20060147446A1 (en) 2006-07-06
EP0862630A2 (de) 1998-09-09
KR100389711B1 (ko) 2003-10-30
EP0862630B1 (de) 2007-06-13
HUP9902327A2 (hu) 1999-10-28
DE69637131T2 (de) 2008-02-07
WO1997017446A2 (en) 1997-05-15
NO982062D0 (no) 1998-05-06
US20030175269A1 (en) 2003-09-18
AU1157697A (en) 1997-05-29

Similar Documents

Publication Publication Date Title
DE69637131D1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
DE69735367D1 (de) THERAPEUTISCHE MULTISPEZIFISCHE VERBINDUNGEN, DIE ANTIKÖRPER GEGEN DEN FCalpha-REZEPTOR ENTHALTEN
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE355288T1 (de) Verbindungen und therapeutische methoden
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
DK0552296T3 (da) Monoklonale antistoffer fra mus
DE59409735D1 (de) ALKOXYALKYLCARBAMATE VON IMIDAZO[1,2-a]PYRIDINEN
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
FR2707166B1 (fr) Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression .
BR9708648A (pt) Muteina de il-6
IT1275623B1 (it) Uso terapeutico e cosmetico degli allumi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties